drugset / Trial / NCT00814372
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
RandomizedParallel-groupTriple-blindTreatment
Summary
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in patients inadequately controlled with a stable dose of metformin (≥ 1500 mg/day).
Timeline
- Start
- 2008-12
- Primary completion
- 2010-02
- Completion
- 2010-02
Outcome
Outcome not reported
Stopped: “MBX-102 did not meet the target efficacy profile of HbA1c change.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arhalofenate | Unknown | 400 mg | Oral |
| Subject | Arhalofenate | Unknown | 600 mg | Oral |
| Comparator | Pioglitazone | Small molecule | 45 mg | — |
| Background | Metformin | Small molecule | 1500 mg/kg | — |